Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Olympus Corp to withdraw from biologics business and lowers full-year consolidated net profit outlook for FY 2014


Friday, 28 Feb 2014 02:00am EST 

Olympus Corp:To withdraw from biologics business and dissolve a wholly owned sub-subsidiary Olympus Biotech Corporation, which will complete liquidation in 2017.Sees extraordinary loss of about 15 bln yen to 19 bln yen, for withdrawal from biologics business, for fiscal year ending March 31, 2014.Full-year consolidated outlook for revenue of 720,000 mln yen, for fiscal year ending March 31, 2014.Full-year operating profit outlook of 72,500 mln yen.Full-year ordinary profit outlook of 50,000 mln yen.Full-year net profit (loss) outlook of (4,000)~0 mln yen lowered from 13,000 mln yen.Full-year earnings (loss) per share outlook of (12.05)~0.00 yen lowered from 37.98 yen.Net profit outlook lowered due to withdrawal from biologics business.FY 2014 revenue of 718,880 mln yen, operating profit of 74,670 mln yen and net profit of 15,740 mln yen - Thomson Reuters I/B/E/S. 

Company Quote

3710.0
20.0 +0.54%
24 Oct 2014